Ascorbic acid Ferric derisomaltose (Monoferric) was approved in the United States in January 2020, for the treatment of<unk> . Treatment should take into account the cause and severity of the condition. If the<unk>  is a result of blood loss or another underlying cause, treatment is geared toward addressing the underlying cause. Most cases of<unk>  are treated with oral<unk>  supplements. In severe acute cases, treatment measures are taken for immediate management in the interim, such as blood transfusions or intravenous<unk> . For less severe cases, treatment of<unk>  includes dietary changes to incorporate<unk> -rich foods into regular oral intake and oral<unk>  supplementation. Foods rich in ascorbic acid (vitamin C) can also be beneficial, since ascorbic acid enhances<unk>  absorption. Oral<unk>  supplements are available in multiple forms. Some are in the form of pills and some are drops for children. Most forms of oral<unk>  replacement therapy are absorbed well by the small intestine; however, there are certain preparations of<unk>  supplements that are designed for longer release in the small intestine than other preparations. Oral<unk>  supplements are best taken up by the body on an empty stomach because food can decrease the amount of<unk>  absorbed from the small intestine. The dosing of oral<unk>  replacement therapy is as much as 100–200 mg per day in adults and 3–6 mg per kilogram in children. This is generally spread out as 3-4 pills taken throughout the day. The various forms of treatment are not without possible adverse side effects.<unk>  supplementation by mouth commonly causes negative gastrointestinal effects, including constipation, nausea, vomiting, metallic taste to the oral<unk>  and dark colored stools. Constipation is reported by 15-20% of patients taking oral<unk>  therapy. Preparations of<unk>  therapy that take longer to be absorbed by the small intestine (extended release<unk>  therapy) are less likely to cause constipation. It can take six months to one year to get blood levels of<unk>  up to a normal range and provide the body with<unk>  stores. Oral<unk>  replacement may not be effective in cases of<unk><unk>  due to malabsorption, such as celiac disease, inflammatory bowel disease, or H. pylori infection; these cases would require treatment of the underlying disease to increase oral absorption or intravenous<unk>  replacement. As<unk>  becomes more severe, if the anemia does not respond to oral treatments, or if the treated person does not tolerate oral<unk>  supplementation, then other measures may become necessary. Two options are intravenous<unk>  injections and blood transfusion. Intravenous can be for people who do not tolerate oral<unk> , who are unlikely to respond to oral<unk> , or who require<unk>  on a long-term basis. For example, people receiving dialysis treatment who are also getting erythropoietin or another erythropoiesis-stimulating agent are given parenteral<unk> , which helps the body respond to the erythropoietin agents to produce red blood cells. Intravenous<unk>  can induce an allergic response that can be as serious as anaphylaxis, although different formulations have decreased the likelihood of this adverse effect. In certain cases intravenous<unk>  is both safer and more effective than the oral route. For patients with severe anemia such as from blood loss, or who have severe symptoms such as cardiovascular instability, a blood transfusion may be considered.
Iron-deficiency anemia
Lead poisoning
Iatrogenic anemia
Megaloblastic anemia
Hemoglobinemia
Nutritional anemia
Sideroblastic anemia
Myelophthisic anemia